These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31449507)

  • 1. Management of advanced phase myeloproliferative neoplasms.
    Marcellino B; Mascarenhas J
    Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.
    Ajufo HO; Waksal JA; Mascarenhas JO; Rampal RK
    Ther Adv Hematol; 2023; 14():20406207231177282. PubMed ID: 37564898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated and blast phase myeloproliferative neoplasms.
    Saliba AN; Gangat N
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
    Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
    [No Abstract]   [Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
    Cherington C; Slack JL; Leis J; Adams RH; Reeder CB; Mikhael JR; Camoriano J; Noel P; Fauble V; Betcher J; Higgins MS; Gillette-Kent G; Tremblay LD; Peterson ME; Olsen JJ; Tibes R; Mesa RA
    Leuk Res; 2012 Sep; 36(9):1147-51. PubMed ID: 22578777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
    Bewersdorf JP; Rampal RK
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.
    Marcellino BK; Hoffman R; Tripodi J; Lu M; Kosiorek H; Mascarenhas J; Rampal RK; Dueck A; Najfeld V
    Blood Adv; 2018 Dec; 2(24):3581-3589. PubMed ID: 30563882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
    Tefferi A; Alkhateeb H; Gangat N
    Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
    Khan M; Siddiqi R; Gangat N
    Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
    Patel AA; Odenike O
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment.
    Vakil E; Tefferi A
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S37-45. PubMed ID: 22035746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for myeloproliferative neoplasms (MPN).
    Hofmann S; Babiak A; Greiner J
    Curr Cancer Drug Targets; 2011 Jan; 11(1):72-84. PubMed ID: 21062247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
    Kundranda MN; Tibes R; Mesa RA
    Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
    Chen D; Fuda F; Weinberg O
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():78-81. PubMed ID: 34288445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.
    Salit RB; Deeg HJ
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1023-35. PubMed ID: 25459177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.
    Patel AA; Yoon JJ; Johnston H; Davidson MB; Shallis RM; Chen EC; Burkart M; Oh TS; Iyer SG; Madarang E; Muthiah C; Gross I; Dean R; Kassner J; Viswabandya A; Madero-Marroquin R; Rampal RK; Guru Murthy GS; Bradley T; Abaza Y; Garcia JS; Gupta V; Pettit KM; Cursio JF; Odenike O
    Blood Adv; 2024 Jul; 8(13):3468-3477. PubMed ID: 38739724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy.
    Javorniczky NR; Wehrle J; Ihorst G; Hupfer V; Aumann K; Pfeifer D; Niemöller C; Bleul S; Pantic M; Werner M; Duyster J; Finke J; Engelhardt M; von Bubnoff N; Waller CF; Pahl HL; Becker H
    Leuk Res; 2020 Nov; 98():106454. PubMed ID: 32971364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.